It is tempting to speculate that the ability of these drugs to inhibit TBX2 and TBX3 may be through their inhibition of the Wnt signalling pathway because it has been previously reported to regulate TBX2 in pancreatic and prostate cancer and TBX3 in liver cancer. This evidence concerns the gene TBX2 and prostate carcinoma.